Clinical Trial Search

Primary: Geometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV) — 248.0; 254.2; 389.1; 368.6 gpELISA Units/mL — p=<0.001

Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716

Primary: Number of Participants Who Received the Herpes Zoster Vaccine — 500; 2089 Participants

Primary: Number of Subjects With Confirmed Herpes Zoster (HZ) Cases — 3; 2; 1; 6 Participants — p=<0.0001

Primary: Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall — 69; 341 Participants

Primary: Number of Subjects by Frailty Status, at Baseline — 11518; 12290; 3037; 131 Participants

Primary: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) — 5175; 963; 4422 Participants

Primary: Number of Subjects With Any Episodes of Herpes Zoster (HZ) — 17; 6; 23; 169 Participants — p=<0.0001

Primary: Vaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination — 0; 0; 100; 101 Participants

Primary: Cell-Mediated Immunity (CMI) in Terms of Frequencies of Antigen-specific CD4 T Cells — 726.19; 567.52 cells/million T-cells

Primary: Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA — 74; 26; 26; 22 Participants

Primary: Incidence Rate of Confirmed Herpes Zoster (HZ) Cases — 0.0; 4.1 Cases per 1000 person-years

Primary: Percentage of Participants Showing a Vaccine Response for Anti-glycoprotein E (gE) — 85.7; 7.8 Percentage of participants

Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)

Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001